Mesa Laboratories (MLAB)
(Delayed Data from NSDQ)
$109.73 USD
+2.48 (2.31%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $109.72 -0.01 (-0.01%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth F Momentum D VGM
Average Brokerage Rating
Current ABR | 1.67 |
ABR (Last week) | 1.67 |
# of Recs in ABR | 3 |
Average Target Price | $127.50 |
LT Growth Rate | NA |
Industry | Medical - Instruments |
Industry Rank by ABR | 62 of 252 |
Current Quarter EPS Est: | 2.33 |
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.67 | 1.67 | 1.67 | 1.67 | 1.67 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
1/4/2024 | Evercore Partners | Vijay Kumar | Not Available | Strong Buy |
10/16/2023 | KeyBanc Capital Markets | Paul Knight | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.